Johnson & Johnson (NYSE: JNJ) has announced positive results from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) ...

Living with ulcerative colitis doesn’t mean giving up the flavors you love. You can enjoy delicious meals without painful ...

Tremfya was administered subcutaneously for both induction and maintenance, inducing a clinical response in 65% of moderate to severe UC patients.

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

US healthcare giant Johnson & Johnson has announced data from the Phase III ASTRO study of Tremfya (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ...

Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...

MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal bacterial strains. It is designed to deliver long-term remission to UC ...

Johnson & Johnson announced data from the Phase 3 ASTRO study of TREMFYA subcutaneous, SC, induction therapy in adults with moderately to ...

A nationwide study of older adults in Sweden suggests a suspected link between antibiotic use and microscopic colitis is more ...

The intestinal epithelium is a highly dynamic barrier that regulates digestion, absorption, immune responses, and ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...